Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease

Paul Nestel, Elizabeth Barnes, Andrew Tonkin, John Simes, Marion Fournier, Harvey White, David Colquhoun, Stefan Blankenberg, David Sullivan

    Research output: Contribution to journalArticlepeer-review

    82 Citations (Scopus)


    OBJECTIVE - : Association between lipoprotein(a) (Lp(a)) level and a first-ever coronary (CHD) event is recognized. Less is evident in patients with overt CHD and stable symptoms in whom we investigated associations between Lp(a) and future events. APPROACH AND RESULTS - : Relationships between Lp(a) concentration and CHD and cardiovascular disease outcomes during 6 years' median follow-up were evaluated in the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study. Lp(a) concentrations were measured in plasma from 7863 patients who had sustained a previous coronary event and been randomized to pravastatin or placebo. Lp(a) levels were categorized by lowest half, third quartile, 75th to 90th percentile, and highest decile. The prognostic value of Lp(a) on outcomes was assessed by fitting a Cox proportional-hazards model after adjustment for other risk factors and baseline cardiovascular disorders. The prognostic value of a change in Lp(a) at year 1 categorized by quartiles was assessed using Cox regression in a landmark model incorporating the above factors and baseline levels. Baseline Lp(a) concentration was associated with total CHD events (P<0.001), total cardiovascular disease events (P=0.002), and coronary events (P=0.03). Greatest risk occurred at >73 mg/dL, upper decile. For events after year 1, an increase in Lp(a) at 1 year was associated with adverse outcomes for total CHD events and total cardiovascular disease events (P=0.002 each). CONCLUSIONS - : In the LIPID study, baseline Lp(a) was associated with future cardiovascular disease and CHD events. Increased Lp(a) concentrations after 1 year were also associated with future events, supporting measurement of Lp(a) for risk assessment of patients with known CHD.

    Original languageEnglish
    Pages (from-to)2902-2908
    Number of pages7
    JournalArteriosclerosis Thrombosis and Vascular Biology
    Issue number12
    Publication statusPublished - Dec 2013


    • Cardiovascular diseases
    • Coronary disease
    • Lipoprotein(a)
    • Pravastatin


    Dive into the research topics of 'Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease'. Together they form a unique fingerprint.

    Cite this